CD80 and acute myeloid leukemia: Recent studies have shown that in paired patient samples collected from AML patients at the time of diagnosis and at post-transplant relapse there is increased expression of inhibitory molecules such as PD-L1, CD276/B7–H3 and CD155/PVRL2 and this phenomenon is observed in up to 40% of cases at relapse (82).